Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Prostate Cancer | Primary research

RETRACTED ARTICLE: Circular RNA ITCH suppressed prostate cancer progression by increasing HOXB13 expression via spongy miR-17-5p

Authors: Xuegang Wang, Rong Wang, Zhun Wu, Peide Bai

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Circular RNA Itchy E3 ubiquitin protein ligase (Circ-ITCH) is significantly down-regulated in various kinds of tumors, however, the mechanisms of action and functions of circITCH gene in prostate cancer (PC) are still under investigation. The mail goal of this research was to study the functional role of Circ-ITCH gene in prostate cancer and to illuminate the function role of circ-ITCH gene in prostate cancer by targeting miR-17-5p/HOXB13.

Methods

RT-qPCR was applied to measure the expression level of circ-ITCH and miR-17-5p in PC cell lines and tissues. CCK-8, colony formation, Brdu incorporation labeling and flow cytometry assays were applied to detect the effects of circ-ITCH and miR-17-5p on proliferation and cell apoptosis. Target gene prediction and screening, luciferase reporter gene assays were utilized to assess downstream target genes of miR-17-5p and Circ-ITCH. The protein and expression of HOXB13 gene were measured by Western blotting and RT-qPCR.

Results

CircITCH was significantly reduced in PC cell lines and tissues. Low circITCH expression level was highly related with preoperative PSA, tumor stage and Gleason score. Overexpression of circITCH can inhibit the malignant phenotype of prostate cancer. There was a high negative relationship between the expression level of microRNA-17-5p and circITCH in PC tissues, however, there existed a positive relationship between the expression of HOXB13 and circITCH. CircITCH acted as a sponge of miR-17-5p to increase HOXB13 gene expression. In addition, miR-17-5p overexpression or HOXB13 silencing can reduce the carcinogenic effects of circICCH in prostate cancer.

Conclusion

CircITCH promoted prostate cancer progression by regulating the HOXB13/miR-17-5p axis, and circITCH have a potential usage as therapeutic target for PC tumors.
Literature
1.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187.PubMedCrossRef
2.
Vordermark D. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;26(5):565–6.
3.
Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Can Res. 2008;68(11):4447–54.CrossRef
4.
Viktorov AA, Zharinov GM, Neklasova NJ, Morozova EE. Prediction of life expectancy for prostate cancer patients based on the kinetic theory of aging of living systems. Adv Gerontol. 2017;7(4):290–5.CrossRef
5.
Kalra S, Basourakos S, Abouassi A, Achim M, Volk RJ, Hoffman KE, et al. The implications of ageing and life expectancy in prostate cancer treatment. Nat Rev Urol. 2016;13(5):289–95.PubMedCrossRef
6.
Daskivich TJ, Lai J, Dick AW, Setodji CM, Hanley JM, Litwin MS, et al. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer. 2015;120(23):3642–50.CrossRef
7.
Walz J, Graefen M, Huland H. Basic principles of anatomy for optimal surgical treatment of prostate cancer. World J Urol. 2007;25(1):31–8.PubMedCrossRef
8.
Akaza H, Chang SJ, Chen KK, Esuvaranathan K, Fujioka T, Hirao Y, et al. The 2nd conference on Asian trends in prostate cancer hormone therapy. Gan to Kagaku Ryoho Cancer Chemother. 2004;31(8):1285–95.
9.
Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Urol. 2016;195(1):96.CrossRef
10.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perezlopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2016;195(4):925–8.
11.
Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011;102(1):245–52.PubMedCrossRef
12.
13.
Glažar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. Rna-a Publ Rna Soc. 2014;20(11):1666–70.CrossRef
14.
Zhang X, Yang D, Wei Y. Overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer. Oncotargets Ther. 2018;11:3979–87.CrossRef
15.
Xie H, Ren X, Xin S, Lan X, Lu G, Yuan L, et al. Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. Oncotarget. 2016;7(18):26680–91.PubMedPubMedCentralCrossRef
16.
Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. Rna-a Publ Rna Soc. 2013;19(2):141–57.CrossRef
17.
Zhang S, Zhu D, Li H, Li H, Feng C, Zhang W. Characterization of circRNA-associated-ceRNA networks in a senescence-accelerated mouse prone 8 brain. Mol Ther. 2017;25(9):2053.PubMedPubMedCentralCrossRef
18.
Huang G, Hua Z, Shi Y, Wu W, Cai H, Chen X. cir-ITCHPlays an inhibitory role in colorectal cancer by regulating the Wnt/β-catenin pathway. PLoS ONE. 2015;10(6):e0131225.PubMedPubMedCentralCrossRef
19.
Wan L, Zhang L, Fan K, Cheng ZX, Sun QC, Wang JJ. Circular RNA-ITCH suppresses lung cancer proliferation via inhibiting the Wnt/Î2-CATENIN PATHWAY. Biomed Res Int. 2016;2016(1):1579490.PubMedPubMedCentral
20.
Li F, Zhang L, Li W, Deng J, Zheng J, An M, et al. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway. Oncotarget. 2015;6(8):6001–13.PubMedPubMedCentralCrossRef
21.
Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2012;104(19):1518–23.PubMed
22.
23.
Shaw G, Oliver RT. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. Surg Oncol. 2009;18(3):275–82.PubMedCrossRef
24.
Rick FG, Block NL, Schally VA. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Oncol Targets Ther. 2013;6:391–402.CrossRef
25.
Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15 Spec No 1(suppl_1):R17.CrossRef
26.
27.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.PubMedCrossRef
28.
Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE. 2012;7(2):e30733.PubMedPubMedCentralCrossRef
29.
Kulcheski FR, Christoff AP, Margis R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 2016;238:42–51.PubMedCrossRef
30.
Toit AD. RNA: circular RNAs as miRNA sponges. Nat Rev Mol Cell Biol. 2013;14(4):195.CrossRef
31.
Yang W, Du WW, Li X, Yee AJ, Yang BB. Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis. Oncogene. 2015;35(30):3919.PubMedCrossRef
32.
Du WW, Fang L, Yang W, Wu N, Awan FM, Yang Z, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 2016;24(2):357.PubMedPubMedCentralCrossRef
33.
Pan H, Li T, Jiang Y, Pan C, Ding Y, Huang Z, et al. Overexpression of circular RNA ciRS-7 abrogates the tumor suppressive effect of miR-7 on gastric cancer via PTEN/PI3 K/AKT signaling pathway. J Cellular Biochem. 2018;119(1):440–6.CrossRef
34.
Zhong Y, Du Y, Xue Y, Mo Y, Fan C, Fang X, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17(1):79.PubMedPubMedCentralCrossRef
35.
Dai Y, Li D, Chen X, Tan X, Gu J, Chen M, et al. Circular RNA myosin light chain kinase (MYLK) promotes prostate cancer progression through modulating Mir-29a expression. Med Sci Monit Int Med J Exp Clin Res. 2018;24:3462–71.
36.
Yang C, Yuan W, Yang X, Li P, Wang J, Han J, et al. Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. Mol Cancer. 2018;17(1):19.PubMedPubMedCentralCrossRef
37.
Xing Z, Min Z, Rong Y, Zhao W, Hu X, Gan J. Identification and comparison of novel circular RNAs with associated co-expression and competing endogenous RNA networks in pulmonary tuberculosis. Oncotarget. 2017;8(69):113571–82.CrossRef
38.
Fan M, Sethuraman A, Brown M, Sun W, Pfeffer LM. Systematic analysis of metastasis-associated genes identifies miR- 17-5p as a metastatic suppressor of basal-like breast cancer. Breast Cancer Res Treat. 2014;146(3):487–502.PubMedPubMedCentralCrossRef
39.
Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 2006;26(21):8191–201.PubMedPubMedCentralCrossRef
40.
Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141–9.PubMedPubMedCentralCrossRef
41.
42.
Edwards S, Campbell C, Flohr P, Shipley J, Giddings I, Tepoele R, et al. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. BRJ Cancer. 2005;92(2):376–81.CrossRef
43.
Jung C, Kim RS, Lee SJ, Wang C, Jeng MH. HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Can Res. 2004;64(9):3046–51.CrossRef
Metadata
Title
RETRACTED ARTICLE: Circular RNA ITCH suppressed prostate cancer progression by increasing HOXB13 expression via spongy miR-17-5p
Authors
Xuegang Wang
Rong Wang
Zhun Wu
Peide Bai
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0994-8

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal metaplasia

Primary research

MicroRNA-96-3p promotes metastasis of papillary thyroid cancer through targeting SDHB

Primary research

TGF-β1 stimulates epithelial–mesenchymal transition and cancer-associated myoepithelial cell during the progression from in situ to invasive breast cancer

Primary research

Contribution of voltage-gated sodium channel β-subunits to cervical cancer cells metastatic behavior

Primary research

Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis

Primary research

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits